Get started

PHARMA

Endo International Bullish News | Upside PotentialEndo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules. According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com) Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca) "We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin. Please leave me a message if you want to test the buy and sell indicators that i am using.
ELong
by BuySellMarketMaker
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020 ---> Lockdowns worldwide due to Covid-19 - - - - - - - - - - - - - - - - - - - - - - - - - - - GlaxoSmithKline plc ( GSK ) LSE:GSK GlaxoSmithKline plc ( GSK ) is a British multinational pharmaceutical company headquartered in Brentford, England. Price decrease of 9.50% - - - - - - - - - - - - - - - - - - - - - - - - - - - Sorrento Therapeutics Inc. NASDAQ:SRNE Sorrento Therapeutics , Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA Price increase of 230% - - - - - - - - - - - - - - - - - - - - - - - - - - - As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise. Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc . Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first. That is true, at all time, and even more so now, in this Covid-branded and forever altered world. Francois Normandeau Institutional Research Director for ADX-BRIEFING P.S. Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all. See you there.
S
by Pine_Academy
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020 ---> Lockdowns worldwide due to Covid-19 - - - - - - - - - - - - - - - - - - - - - - - - - - - GlaxoSmithKline plc (GSK) LSE:GSK GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England. Price decrease of 9.50% - - - - - - - - - - - - - - - - - - - - - - - - - - - Sorrento Therapeutics Inc. NASDAQ:SRNE Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA Price increase of 230% - - - - - - - - - - - - - - - - - - - - - - - - - - - As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise. Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc. Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first. That is true, at all time, and even more so now, in this Covid-branded and forever altered world. Francois Normandeau Institutional Research Director for ADX-BRIEFING P.S. Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all. See you there.
S
by Pine_Academy
Sunpharma - Preparing for its Elliot wave 3Sun pharma is the biggest contributor in the Indian Pharma Index. So far, it has acted like a tired lion however, it seems the lion is ready to claim the kingship all over again. Sun pharma has broken its 3-year downward trendline. RSI has already passed its complexion point. It completed its corrective wave (2) at 450 levels around September. It is all set to touch 630, 750 & 800 levels. 800 would be a crucial level to watch and any correction from those levels will be another buying opportunity.
NSE:SUNPHARMALong
by akumar1057
PHARMA (30/11/2020) consolidating in ascending triangleIn H4, the stock is forming price action in ascending triangle pattern. Currently is consolidating between 5.42 and 5.80. A good entry would be after it breakout from the triangle @ EP 5.86 with Support at 5.38. TP is at 6.73 and new 52WH 8.25 (Fibo 1.272) - RRR 1:1.8 EP 5.86 TP 6.73 / 8.25 SL 5.38 Stochastic shows a pullback signal, MACD didn’t signal any breakout, and RSI didn’t show any good momentum for entry now. PHARMA is one of market leader in Pharmaceutical sector with competitive balanced float (21% of 1440M shares) compared to its sector competitor AHEALTH (23% of 1780M shares). However, current vaccine sentiment will definitely help PHARMA in the long run. TAYOR
MYX:PHARMALong
by sothye